We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
Squarepoint
76
Squarepoint
New York
– -$33.4M -253,193 Closed
AA
77
AQR Arbitrage
Connecticut
– -$33.3M -252,316 Closed
BNP Paribas Financial Markets
78
BNP Paribas Financial Markets
France
– -$32.7M -247,848 Closed
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
– -$31.7M -240,601 Closed
QC
80
Quantessence Capital
New York
– -$30.3M -229,788 Closed
PAM
81
PSquared Asset Management
Switzerland
– -$30.2M -229,086 Closed
ECP
82
Empyrean Capital Partners
California
– -$30.1M -228,000 Closed
HM
83
Harvest Management
New York
– -$29.7M -225,000 Closed
TCM
84
Tang Capital Management
California
– -$29M -220,000 Closed
AGP
85
Artia Global Partners
Florida
– -$29M -219,719 Closed
CAU
86
Caxton Associates (UK)
– -$28.3M -214,783 Closed
Citigroup
87
Citigroup
New York
– -$26.7M -202,695 Closed
GCIA
88
Gabelli & Co Investment Advisers
New York
– -$26.7M -202,300 Closed
OGC
89
One68 Global Capital
New York
– -$26M -197,329 Closed
Two Sigma Investments
90
Two Sigma Investments
New York
– -$25.6M -193,891 Closed
Wellington Management Group
91
Wellington Management Group
Massachusetts
– -$25.1M -190,370 Closed
Swiss National Bank
92
Swiss National Bank
Switzerland
– -$24.4M -185,200 Closed
OBAM
93
ODDO BHF Asset Management
France
– -$24.2M -183,100 Closed
PSAMP
94
P. Schoenfeld Asset Management (PSAM)
New York
– -$23.3M -176,500 Closed
Grantham, Mayo, Van Otterloo & Co (GMO)
95
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
– -$22.8M -173,001 Closed
CSS
96
Cubist Systematic Strategies
Connecticut
– -$21.8M -165,377 Closed
California Public Employees Retirement System
97
California Public Employees Retirement System
California
– -$21.6M -163,937 Closed
SLT
98
St Louis Trust
Missouri
– -$21.6M -163,488 Closed
State of Wisconsin Investment Board
99
State of Wisconsin Investment Board
Wisconsin
– -$21.5M -163,290 Closed
CIEC
100
Crédit Industriel et Commercial
France
– -$21.4M -162,062 Closed
2 3
4
5 6

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.